Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

After spending years developing its endoscopic device treatment for patients with Type 2 diabetes, Fractyl Health is now ...

US-based MicroAire Surgical Instruments has acquired NEOSYAD, a developer of technology for adipose tissue engineering. France-based NEOSYAD recently gained CE marking under the European Union’s ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

The biotech believes that azelaprag can amplify the weight loss achieved with tirzepatide and other obesity drugs, and also improve the body composition of treated patients by preserving muscle ...

The biotech has applied to list on the Nasdaq ... in development and improves upon than the reported half-life of tirzepatide (Zepbound), which is around five days, or semaglutide’s (Ozempic ...

The series A fundraising is the biggest ever for a European biotech firm ... and Company’s competing weight-loss drug, Zepbound (tirzepatide), could post over $11 billion in sales; Mounjaro ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...